Journal: Frontiers in Immunology
Article Title: Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy
doi: 10.3389/fimmu.2024.1307558
Figure Lengend Snippet: C3a, C5a and lyso-Gb3 concentrations in the circulation of FD patients with missense/nonsense mutations. (A–D) C3a, (E–H) C5a and (I–L) lyso-Gb3 concentrations (ng/ml) in samples from (A, E, I) treatment-naiüve (n=17), (B, F, J) FD patients under ERT (n=17) with missense (n=9) or nonsense (n=8) GLA mutations and from FD patients with (C, G, K) missense (n=9) or (D, H, L) nonsense (n=8) GLA mutations before (V0) or under ERT (V1). Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by unpaired t-test (A, B, E, F, I, J ) or paired t- test (C, D, G, H, K, L) . Data in (A, B, E, F, I, J) are shown as mean + SEM. *p<0.05; ***p<0.001.
Article Snippet: For quantification of complement cleavage products C3a/C3a-desArg (C3a) as well as C5a/C5a-desArg (C5a) in serum, commercial C3a (HK354, Hycult Biotech, Uden, Netherlands) and C5a (HK349, Hycult Biotech, Uden, Netherlands) human enzyme-linked immunosorbent assay (ELISA) kits were used according to the manufacturer’s instructions.
Techniques: